	US 11,717,548 B2
	Synthetic oncolytic LNP-replicon RNA and uses for cancer immunotherapy
Darrell J. Irvine, Arlington, MA (US); Karl Dane Wittrup, Chestnut Hill, MA (US); Ron Weiss, Newton, MA (US); Yingzhong Li, Quincy, MA (US); Noor Momin, Cambridge, MA (US); and Yizhou Dong, Dublin, OH (US)
Assigned to Massachusetts Institute of Technology, Cambridge, MA (US); and Ohio State Innovation Foundation, Columbus, OH (US)
Filed by Massachusetts Institute of Technology, Cambridge, MA (US); and Ohio State Innovation Foundation, Columbus, OH (US)
Filed on Jan. 10, 2020, as Appl. No. 16/739,407.
Claims priority of provisional application 62/815,611, filed on Mar. 8, 2019.
Prior Publication US 2020/0281994 A1, Sep. 10, 2020
Int. Cl. A61K 35/768 (2015.01); A61P 35/00 (2006.01); A61K 9/00 (2006.01); C07K 14/54 (2006.01); C12N 7/00 (2006.01)

CPC A61K 35/768 (2013.01) [A61K 9/0019 (2013.01); A61P 35/00 (2018.01); C07K 14/5434 (2013.01); C12N 7/00 (2013.01); C12N 2770/36132 (2013.01)]

22 Claims

1. A synthetic oncolytic virus, comprising:

(i) a lipid nanoparticle comprising N1,N3,N5-tris(3-(didodecylamino)propyl)benzene-1,3,5-tricarboxamide (TT3); and

(ii) a self-amplifying replicon RNA comprising a sequence that encodes an interleukin (IL)-12 molecule;

and

wherein the IL-12 molecule is expressed by the self-amplifying replicon RNA.